title: Psoriatic arthritis.
authors.affiliation: Clinical Training Fellow. Centre for Molecular and Cellular Biology of Inflammation, Division of Immunology, Infection and Inflammatory Disease, King's College London, London.
authors.forename: L E
authors.initials: LE
authors.lastname: Durham
authors.affiliation: Professor in Immunobiology and head of the Centre for Molecular and Cellular Biology of Inflammation, Division of Immunology, Infection and Inflammatory Disease, King's College London, London.
authors.forename: L S
authors.initials: LS
authors.lastname: Taams
authors.affiliation: Consultant Rheumatologist in the Department of Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London SE1 9RT.
authors.forename: B W
authors.initials: BW
authors.lastname: Kirkham
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000068582:Certolizumab Pegol / Q000627:therapeutic use; D000068800:Etanercept / Q000627:therapeutic use; D000069285:Infliximab / Q000627:therapeutic use; D012720:Severity of Illness Index; D000069549:Ustekinumab / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C571216:brodalumab; C529000:golimumab; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol